Trevi Therapeutics/$TRVI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
- Ticker
- $TRVI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 34
- Headquarters
- New Haven, United States
- Website
- www.trevitherapeutics.com
TRVI Metrics
BasicAdvanced
$1.9B
-
-$0.40
1.12
-
Price and volume
Market cap
$1.9B
Beta
1.12
52-week high
$20.22
52-week low
$9.82
Average daily volume
2.4M
Financial strength
Current ratio
38.861
Quick ratio
38.278
Long term debt to equity
0.001
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-69.988
Effective tax rate (TTM)
0.12%
Management effectiveness
Return on assets (TTM)
-17.18%
Return on equity (TTM)
-24.67%
Valuation
Price to book
6.41
Price to tangible book (TTM)
6.41
Price to free cash flow (TTM)
-33.544
Free cash flow yield (TTM)
-2.98%
Free cash flow per share (TTM)
-0.406
Growth
Earnings per share change (TTM)
8.88%
3-year earnings per share growth (CAGR)
13.88%
What the Analysts think about TRVI
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
Analyst projections of the future price of Trevi Therapeutics stock.
Bulls say / Bears say
In the 165-patient CORAL study, Haduvio met its primary endpoint: cough frequency fell 47.9% to 60.2% across doses, versus a 16.9% fall with placebo. This gives Trevi a meaningful efficacy signal to test in Phase 3. (SEC)
Haduvio is being developed for cough linked to IPF, non-IPF lung disease and refractory chronic cough, where Trevi reports no FDA-approved treatment. Its IPF programme has entered Phase 3 and its refractory-cough programme has started Phase 2b, creating more than one potential route to market. (Trevi Therapeutics)
Trevi reported $318.9 million in cash and investments at the end of June and expects this to fund the IPF programme through potential FDA approval, with a cash runway into 2030. That reduces the risk of needing to raise money before its main trial readouts. (Trevi Therapeutics)
Trevi is a single-drug, pre-revenue company, and Haduvio has not yet proved itself in pivotal trials. The company expects key Phase 3 results only in the second half of 2027 and first half of 2028, leaving a long period of clinical and regulatory uncertainty. (SEC)
The company is funding costly trials without product revenue: second-quarter R&D spending rose to $15.2 million from $9.4 million a year earlier. It raised $162.3 million through a share offering in April, and shares outstanding increased from 128.3 million at year-end to 142.4 million by June, diluting existing holders. (SEC)
Management said enrolment was still at an early stage in its two newly launched trials, while the programmes require more than 200 global trial sites. Slow recruitment or site set-up could delay the readouts and increase development costs. (Benzinga)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
TRVI Financial Performance
Revenues and expenses
TRVI Earnings Performance
Company profitability
Upcoming events
No upcoming events
TRVI News
AllArticlesVideos
Funds containing TRVI
Fund name | Fund size | $TRVI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.13% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.13% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.